A Peek Into The Markets: US Stock Futures Down; All Eyes On Jobs Report

Pre-open movers

U.S. stock futures traded lower in early pre-market trade. Data on nonfarm payrolls and unemployment rate for June will be released at 8:30 a.m. ET.

Futures for the Dow Jones Industrial Average dropped 38 points to 26,932, while the Standard & Poor’s 500 index futures fell 5.3 points to 2,995.00. Futures for the Nasdaq 100 index declined 15.75 points to 7,871.75.

Oil prices traded mixed as Brent crude futures rose 0.5% to trade at $63.60 per barrel, while US WTI crude futures fell 0.8% to trade at $56.89 a barrel.

A Peek Into Global Markets

European markets were lower today, with the Spanish Ibex Index falling 0.4%, STOXX Europe 600 Index falling 0.4% and German DAX 30 index dropping 0.4%. The UK's FTSE index was trading lower by 0.4%, while French CAC 40 Index slipped 0.3%.

In Asian markets, Japan’s Nikkei Stock Average rose 0.2%, Hong Kong’s Hang Seng Index slipped 0.07%, China’s Shanghai Composite Index rose 0.19% and India’s BSE Sensex fell 0.99%.

Broker Recommendation

Analysts at Raymond James downgraded Senseonics Holdings, Inc. SENS from Outperform to Market Perform.

Senseonics shares fell 2.7 percent to $1.84 in pre-market trading.

Breaking News

Karyopharm Therapeutics Inc KPTI announced FDA approval of XPOVIO for treatment of patients with relapsed, refractory multiple myeloma.

Alexion Pharmaceuticals, Inc. ALXN disclosed that ULTOMIRIS has received marketing authorization from the European Commission for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria.

WPP PLC WPP reported the acquisition of majority stake in Italian technology-driven creative agency, Aquest.

Grifols, S.A. GRFS reported the FDA approval of Xembify, its new 20% subcutaneous immunoglobulin for treating primary immunodeficiencies.